-
公开(公告)号：US11207392B2
公开(公告)日：2021-12-28
申请号：US16312246
申请日：2017-06-30
发明人： Patrick Soon-Shiong , Kayvan Niazi , Shahrooz Rabizadeh , Hans G. Klingemann , Laurent H. Boissel , Barry J. Simon
摘要： Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
-
公开(公告)号：US20170312351A1
公开(公告)日：2017-11-02
申请号：US15468046
申请日：2017-03-23
IPC分类号： A61K39/00 , C12N7/00 , C12N15/86 , G06F19/18 , A61K39/39 , C07K14/74 , C07K14/705 , C07K7/06
CPC分类号： A61K39/0011 , A61K39/39 , A61K2039/5254 , A61K2039/5256 , A61K2039/57 , A61K2039/572 , A61K2039/70 , C07K7/06 , C07K14/70539 , C07K14/70596 , C07K2319/01 , C07K2319/06 , C07K2319/40 , C07K2319/95 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10334 , C12N2710/10343 , C12N2840/002 , G16B20/00
摘要： Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.
-
公开(公告)号：US20210223231A1
公开(公告)日：2021-07-22
申请号：US16076280
申请日：2017-02-16
摘要： Ex vivo determination of increased tumor immunogenicity of a tumor biopsy is used as a guide to identify immunotherapy of a tumor in a patient. Most preferably, the ex vivo tests will include exposure of biopsy samples to stress conditions to produce pretreated tumor cells that are then assayed with immune competent cells for increased activation or activity. Test conditions include exposure of the biopsy samples to immune stimulatory compositions, antibodies against neoepitopes, and/or modified cells, and an increase of immunogenicity is preferably determined by their exposure to T cells and/or NK cells.
-
公开(公告)号：US11229668B2
公开(公告)日：2022-01-25
申请号：US16483978
申请日：2018-02-08
发明人： Shahrooz Rabizadeh , Kayvan Niazi , Patrick Soon-Shiong , Hing Wong , Wenxin Xu
IPC分类号： A61K35/17 , A61K31/675 , C07K14/52 , C12N15/86
摘要： Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.
-
公开(公告)号：US11585805B2
公开(公告)日：2023-02-21
申请号：US16076280
申请日：2017-02-16
IPC分类号： G01N33/574 , G01N33/50 , G01N33/68
摘要： Ex vivo determination of increased tumor immunogenicity of a tumor biopsy is used as a guide to identify immunotherapy of a tumor in a patient. Most preferably, the ex vivo tests will include exposure of biopsy samples to stress conditions to produce pretreated tumor cells that are then assayed with immune competent cells for increased activation or activity. Test conditions include exposure of the biopsy samples to immune stimulatory compositions, antibodies against neoepitopes, and/or modified cells, and an increase of immunogenicity is preferably determined by their exposure to T cells and/or NK cells.
-
公开(公告)号：US11439697B2
公开(公告)日：2022-09-13
申请号：US17391694
申请日：2021-08-02
发明人： Patrick Soon-Shiong , Kayvan Niazi , Shahrooz Rabizadeh , Hans G. Klingemann , Laurent H. Boissel , Barry J. Simon
摘要： Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
-
公开(公告)号：US20210386844A1
公开(公告)日：2021-12-16
申请号：US17461319
申请日：2021-08-30
摘要： Immunotherapeutic methods and compositions are contemplated in which neoepitopes and/or tumor associated antigens are delivered to dendritic cells via an adenoviral expression system that targets MHC-I and/or MHC-II presentation systems and that further provides one or more recombinant peptides to stimulate T cell activation and interfere with checkpoint inhibition. Treatment is further supported by transfusion of NK cells, which may be modified to have a high affinity CD16 receptor and/or a chimeric antigen receptor that binds to one or more neoepitopes and/or tumor associated antigens.
-
公开(公告)号：US20200171137A1
公开(公告)日：2020-06-04
申请号：US16783734
申请日：2020-02-06
摘要： Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
-
公开(公告)号：US11154597B2
公开(公告)日：2021-10-26
申请号：US15468046
申请日：2017-03-23
IPC分类号： A61K39/00 , A61K39/39 , C07K7/06 , C07K14/74 , C07K14/705 , C12N7/00 , C12N15/86 , G16B20/00 , G16B20/20
摘要： Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.
-
公开(公告)号：US11071774B2
公开(公告)日：2021-07-27
申请号：US16783734
申请日：2020-02-06
发明人： Patrick Soon-Shiong , Kayvan Niazi , Shahrooz Rabizadeh , Hans G. Klingemann , Laurent H. Boissel
摘要： Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
-
-
-
-
-
-
-
-
-
搜索结果
78 条记录 (耗时 0.016 秒)
